Summaries
COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response
The purpose of this guideline is to maximise the safety of children and adults who have gastrointestinal or liver conditions treated with drugs affecting the immune response during the COVID-19 pandemic.
Early identification and referral of liver disease in infants
This Guidelines summary is based on guidance included within the Children’s Liver Disease Foundation Yellow Alert Pack, written to provide general guidelines on the early identification of liver disease in infants and their referral where appropriate.
BSG liver blood tests guideline
This summary covers the key points for GPs to consider when interpreting results from liver blood tests and how to respond to detected abnormalities.
NICE non-alcoholic fatty liver disease guideline
A summary of NICE guidance on non-alcoholic fatty liver disease. Includes identification, lifestyle advice, and pharmacological treatment.
NICE cirrhosis guideline
A useful and concise summary on the assessment and management of cirrhosis. Recommendations cover diagnosis, monitoring, and managing complications.
Educational resources
Non-alcoholic steatohepatitis: identification, management, and referral pathways
This webinar has been initiated and commissioned by Intercept Pharma UK and Ireland Ltd and organised in partnership with Guidelines. Intercept Pharma UK and Ireland Ltd has reviewed the scope of the webinar, commissioned the speakers, and approved all materials related to the webinar. The speakers have been paid an ...
Test and reflect
Non-alcoholic steatohepatitis: identification, management, and referral pathways
COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response
Early identification and referral of liver disease in infants
BSG liver blood tests guideline
NICE non-alcoholic fatty liver disease guideline